期刊文献+

低剂量多巴胺对急性心衰合并肾功能不全患者的影响 被引量:5

Effect of Low-Dose Dopamine on the Patients of Acute Heart Failure with Renal Dysfunction
原文传递
导出
摘要 目的:探讨低剂量多巴胺能否通过利尿作用改善急性左心衰患者的充血症状以及肾功能。方法:将2013年9月至2013年12月我院收治的80例急性心衰合并肾功能不全的患者随机分为对照组和治疗组,每组各40例。对照组给予常规治疗,治疗组在常规治疗的基础上加用小剂量多巴胺静脉泵入48小时。观察和比较两组患者48小时内的总尿量及血清胱抑素C的变化、充血症状、肾功能及临床疗效的差异。结果:与对照组相比,治疗组48小时总尿量、血清胱抑素C的变化、体重变化、BNP变化、肌酐变化、进展性心衰发生率、死亡率、治疗失败患者比例均无明显差异(P>0.05)。结论:低剂量多巴胺不能在利尿治疗基础上减轻急性心力衰竭并发肾功能不全患者的充血症状或改善肾功能。 Objective: To investigate the effect of low-dose dopamine on the decongestion symptoms and renal function of patients with acute heart failure. Methods: 80 patients with acute heart failure and renal dysfunction admitted in our hospital from September 2013 to December 2013 were randomized into the treatment group and control group. The control group accepted the conventional treatment, while the treatment group was administered with the same treatment addition of low-dose dopamine. The 48-hour cumulative urine volume, change of serum cystatin C levels, decongestion symptoms, renal function and clinical efficacy were observed and compared. Results: Compared with the control group, low-dose dopamine had no significant effect on the 48-hour cumulative urine volume, change of serum cystatin C level, weight, BNP, creatinine, incidence rate of advanced heart failure, mortality and ratio of failed patients (P〉0.05). Conclusion: Low-dose dopamine couldn't relieve the decongestion symptoms or improve the renal function of patients with acute heart failure and acute renal insufficiency on the basis of diuretic treatment.
出处 《现代生物医学进展》 CAS 2014年第32期6300-6302,6314,共4页 Progress in Modern Biomedicine
基金 黑龙江省自然科学基金项目(D201101)
关键词 多巴胺 急性心力衰竭 肾功能不全 Dopamine Acute Heart Failure Renal Dysfunction
  • 相关文献

参考文献20

  • 1Lindenfeld J, Albert NM, Boehmer JP, et al. Heart Failure Society of America. HFSA 2010 comprehensive heart failure practice guideline [J]. J Card Fail, 2010, 16(6): e1-e194.
  • 2Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2013, 128(16): e240-327.
  • 3Ronco C, McCullough P, Anker SD, et al. Acute Dialysis Quality Initiative (ADQI) Consensus Group. Cardio-renal syndromes: report fromthe consensus conference of the Acute Dialysis Quality Initiative [J]. Eur Heart J, 2010, 31(6):703-711.
  • 4Givertz MM, Teerlink JR, Albert NM, et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research[J]. J Card Fail, 2013, 19(6):371-389.
  • 5Maskin CS, Ocken S, Chadwick B, et al. Comparative systemic and renal effects of dopamine and angiotensin-converting enzyme inhibition with enalaprilat in patients with heart failure[J]. Circulation, 1985, 72(4):846-852.
  • 6ElkayamU, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action[J]. Circulation, 2008, 117(2): 200-205.
  • 7Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial[J].J Card Fail, 2010, 16(12): 922-930.
  • 8Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac,renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes[J].J AmColl Cardiol, 2013, 61(2): 196-206.
  • 9Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failuree with cardiorenal syndrome[J]. N Engl J Med, 2012, 367(24): 2296-2304.
  • 10Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial [J]. Lancet, 2013, 381 (9860):29-39.

同被引文献32

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部